$3.45 Billion is the total value of Perceptive Advisors's 95 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 40.4% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FOLD | AMICUS THERAPEUTICS INC | $347,446,237 | +13.3% | 27,662,917 | 0.0% | 10.07% | +11.2% | |
CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $315,295,382 | +98.5% | 9,918,068 | +52.3% | 9.14% | +94.9% |
LIANBIOsponsored ads | $131,233,268 | +16.3% | 57,558,451 | 0.0% | 3.80% | +14.2% | ||
Buy | ARCELLX INC | $126,998,473 | +7.3% | 4,016,397 | +4.5% | 3.68% | +5.4% | |
Sell | AMYLYX PHARMACEUTICALS INC | $105,130,433 | -40.6% | 4,873,919 | -19.2% | 3.05% | -41.7% | |
IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $98,816,326 | +5.4% | 14,036,410 | -8.5% | 2.86% | +3.5% |
ALDX | ALDEYRA THERAPEUTICS INC | $95,227,213 | -15.5% | 11,350,085 | 0.0% | 2.76% | -17.0% | |
INBX | Buy | INHIBRX INC | $94,083,765 | +37.9% | 3,624,182 | +0.2% | 2.73% | +35.5% |
VRNA | Buy | VERONA PHARMA PLCsponsored ads | $92,955,032 | +69.3% | 4,397,116 | +60.8% | 2.70% | +66.3% |
Sell | NUVALENT INC | $92,555,602 | +54.2% | 2,194,821 | -4.6% | 2.68% | +51.4% | |
AKRO | Buy | AKERO THERAPEUTICS INC | $90,610,116 | +352.4% | 1,940,675 | +270.7% | 2.63% | +344.5% |
PCVX | Buy | VAXCYTE INC | $80,609,253 | +83.8% | 1,614,122 | +38.0% | 2.34% | +80.5% |
MGTX | Buy | MEIRAGTX HLDGS PLC | $76,145,012 | +111.6% | 11,331,103 | +62.7% | 2.21% | +107.8% |
APLS | Buy | APELLIS PHARMACEUTICALS INC | $73,976,570 | +102.0% | 812,037 | +46.2% | 2.14% | +98.2% |
MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $69,989,997 | -55.6% | 302,987 | -53.4% | 2.03% | -56.4% |
RETA | Sell | REATA PHARMACEUTICALS INCcl a | $68,334,204 | -65.4% | 670,206 | -69.1% | 1.98% | -66.0% |
TMCI | Sell | TREACE MED CONCEPTS INC | $56,717,255 | -7.8% | 2,217,250 | -9.2% | 1.64% | -9.5% |
LYRA | Buy | LYRA THERAPEUTICS INC | $52,433,579 | +185.2% | 12,757,562 | +39.5% | 1.52% | +179.9% |
VIR | Buy | VIR BIOTECHNOLOGY INC | $48,036,216 | +1351.7% | 1,958,264 | +1277.2% | 1.39% | +1321.4% |
IMVT | Buy | IMMUNOVANT INC | $47,876,164 | +138.9% | 2,523,783 | +95.4% | 1.39% | +134.5% |
XENE | Sell | XENON PHARMACEUTICALS INC | $47,100,015 | -28.2% | 1,223,377 | -33.2% | 1.36% | -29.5% |
ADMA | ADMA BIOLOGICS INC | $43,911,941 | +11.5% | 11,900,255 | 0.0% | 1.27% | +9.5% | |
RAPT | Sell | RAPT THERAPEUTICS INC | $42,794,819 | +1.8% | 2,288,493 | -0.1% | 1.24% | -0.1% |
VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $42,260,223 | -4.3% | 1,776,386 | +2.3% | 1.22% | -6.1% |
MDT | New | MEDTRONIC PLC | $41,142,700 | – | 467,000 | +100.0% | 1.19% | – |
CBAY | Sell | CYMABAY THERAPEUTICS INC | $40,879,142 | +20.1% | 3,733,255 | -4.4% | 1.18% | +17.9% |
PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $40,594,799 | +82.9% | 1,469,761 | +52.3% | 1.18% | +79.7% |
SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $40,311,440 | -24.7% | 1,537,431 | -26.1% | 1.17% | -26.0% |
IMTX | IMMATICS N.V | $40,291,910 | +67.2% | 3,491,500 | 0.0% | 1.17% | +64.3% | |
ACRIVON THERAPEUTICS INC | $38,981,840 | +2.1% | 3,007,858 | 0.0% | 1.13% | +0.3% | ||
NAUT | NAUTILUS BIOTECHNOLOGY INC | $35,260,154 | +39.7% | 9,111,151 | 0.0% | 1.02% | +37.2% | |
CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $35,083,805 | -38.5% | 1,946,937 | -45.2% | 1.02% | -39.7% |
New | DISC MEDICINE INC | $32,982,007 | – | 742,838 | +100.0% | 0.96% | – | |
Buy | ROIVANT SCIENCES LTD | $31,567,899 | +58.9% | 3,131,736 | +16.3% | 0.92% | +55.9% | |
COGT | Buy | COGENT BIOSCIENCES INC | $31,488,125 | +27.9% | 2,659,470 | +16.5% | 0.91% | +25.6% |
HRMY | Buy | HARMONY BIOSCIENCES HLDGS IN | $31,367,310 | +860.7% | 891,370 | +791.4% | 0.91% | +846.9% |
BBIO | Sell | BRIDGEBIO PHARMA INC | $30,081,647 | -4.9% | 1,748,933 | -8.3% | 0.87% | -6.6% |
ESTA | Sell | ESTABLISHMENT LABS HLDGS INC | $29,154,036 | -8.0% | 424,924 | -9.2% | 0.84% | -9.7% |
VRCA | VERRICA PHARMACEUTICALS INC | $29,074,931 | -11.2% | 5,038,983 | 0.0% | 0.84% | -12.8% | |
ILMN | New | ILLUMINA INC | $27,186,050 | – | 145,000 | +100.0% | 0.79% | – |
ARGX | New | ARGENX SEsponsored adr | $26,891,370 | – | 69,000 | +100.0% | 0.78% | – |
MRTX | Sell | MIRATI THERAPEUTICS INC | $25,981,191 | -55.6% | 719,103 | -54.3% | 0.75% | -56.4% |
RLAY | RELAY THERAPEUTICS INC | $24,405,298 | -23.7% | 1,943,097 | 0.0% | 0.71% | -25.1% | |
TARS | TARSUS PHARMACEUTICALS INC | $23,426,237 | +43.8% | 1,296,416 | 0.0% | 0.68% | +41.2% | |
RCKT | Buy | ROCKET PHARMACEUTICALS INC | $23,215,373 | +56.2% | 1,168,363 | +34.6% | 0.67% | +53.3% |
BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $22,814,783 | -65.1% | 263,207 | -60.9% | 0.66% | -65.8% |
Sell | ZYMEWORKS INC | $20,876,244 | -31.6% | 2,416,232 | -28.5% | 0.60% | -32.9% | |
CABA | Buy | CABALETTA BIO INC | $19,945,950 | +232.8% | 1,545,000 | +113.2% | 0.58% | +226.6% |
OM | Sell | OUTSET MED INC | $19,734,613 | -1.6% | 902,360 | -17.2% | 0.57% | -3.4% |
NTRA | Sell | NATERA INC | $19,720,390 | -49.8% | 405,269 | -42.7% | 0.57% | -50.6% |
AXSM | New | AXSOME THERAPEUTICS INC | $19,509,487 | – | 271,493 | +100.0% | 0.57% | – |
SOLID BIOSCIENCES INC | $18,318,688 | +10.5% | 3,495,933 | 0.0% | 0.53% | +8.6% | ||
ASTRIA THERAPEUTICS INC | $18,238,218 | -37.4% | 2,189,462 | 0.0% | 0.53% | -38.5% | ||
CRY | Sell | ARTIVION INC | $16,009,941 | +12.5% | 931,352 | -14.2% | 0.46% | +10.5% |
BMEA | Buy | BIOMEA FUSION INC | $15,725,879 | +56.0% | 716,441 | +120.4% | 0.46% | +53.0% |
MIRM | MIRUM PHARMACEUTICALS INC | $15,562,512 | +7.7% | 601,566 | 0.0% | 0.45% | +5.6% | |
ITCI | New | INTRA-CELLULAR THERAPIES INC | $15,564,056 | – | 245,800 | +100.0% | 0.45% | – |
TCMD | Sell | TACTILE SYS TECHNOLOGY INC | $15,017,259 | +42.9% | 602,377 | -5.9% | 0.44% | +40.3% |
Sell | ORCHESTRA BIOMED HLDGS INC | $14,370,076 | -67.8% | 2,052,868 | -9.9% | 0.42% | -68.3% | |
ATHA | ATHIRA PHARMA INC | $14,151,970 | +18.0% | 4,797,278 | 0.0% | 0.41% | +15.8% | |
AXGN | Buy | AXOGEN INC | $13,373,825 | +0.4% | 1,464,822 | +3.9% | 0.39% | -1.3% |
FUSN | Sell | FUSION PHARMACEUTICALS INC | $12,849,014 | +23.5% | 2,751,395 | -0.3% | 0.37% | +21.2% |
PRTA | Sell | PROTHENA CORP PLC | $12,605,512 | +9.4% | 184,615 | -22.3% | 0.36% | +7.4% |
CMAX | Buy | CAREMAX INC | $11,872,126 | +24.3% | 3,817,404 | +6.7% | 0.34% | +22.0% |
New | SOLENO THERAPEUTICS INC | $9,471,260 | – | 2,207,753 | +100.0% | 0.28% | – | |
NBIX | NEUROCRINE BIOSCIENCES INC | $9,434,715 | -6.8% | 100,050 | 0.0% | 0.27% | -8.4% | |
TERN | New | TERNS PHARMACEUTICALS INCput | $9,406,250 | – | 1,075,000 | +100.0% | 0.27% | – |
SRPT | Sell | SAREPTA THERAPEUTICS INC | $9,284,594 | -74.2% | 81,074 | -68.9% | 0.27% | -74.7% |
New | BIOHAVEN LTD | $7,674,014 | – | 320,820 | +100.0% | 0.22% | – | |
VKTX | Sell | VIKING THERAPEUTICS INC | $7,150,993 | -50.7% | 441,147 | -49.4% | 0.21% | -51.7% |
XFOR | Sell | X4 PHARMACEUTICALS INC | $6,878,181 | +73.9% | 3,545,454 | -22.0% | 0.20% | +70.1% |
ISEE | Sell | IVERIC BIO INC | $6,609,120 | -45.7% | 168,000 | -66.4% | 0.19% | -46.5% |
New | LANDOS BIOPHARMA INC | $6,255,771 | – | 1,486,991 | +100.0% | 0.18% | – | |
Sell | TYRA BIOSCIENCES INC | $6,130,800 | -22.8% | 360,000 | -27.2% | 0.18% | -24.3% | |
NBTX | NANOBIOTIXsponsored ads | $5,373,186 | +43.8% | 1,059,800 | 0.0% | 0.16% | +41.8% | |
New | VBI VACCINES INC CDA | $4,544,657 | – | 1,381,355 | +100.0% | 0.13% | – | |
New | ACELYRIN INC | $4,180,000 | – | 200,000 | +100.0% | 0.12% | – | |
SOMALOGIC INC | $3,465,000 | -9.4% | 1,500,000 | 0.0% | 0.10% | -11.5% | ||
KRON | KRONOS BIO INC | $3,014,721 | +17.8% | 1,752,745 | 0.0% | 0.09% | +14.5% | |
QTRX | QUANTERIX CORP | $2,931,500 | +100.1% | 130,000 | 0.0% | 0.08% | +97.7% | |
ENVVENO MEDICAL CORPORATION | $2,407,374 | -34.2% | 781,615 | 0.0% | 0.07% | -35.2% | ||
OMIC | Sell | SINGULAR GENOMICS SYSTEMS IN | $1,961,468 | -50.6% | 2,363,214 | -28.0% | 0.06% | -51.3% |
New | LEAP THERAPEUTICS INC | $1,836,474 | – | 586,733 | +100.0% | 0.05% | – | |
ARQT | New | ARCUTIS BIOTHERAPEUTICS INCput | $1,417,500 | – | 300,000 | +100.0% | 0.04% | – |
TVTX | TRAVERE THERAPEUTICS INC | $1,393,889 | -31.7% | 90,748 | 0.0% | 0.04% | -33.3% | |
PNT | New | POINT BIOPHARMA GLOBAL INCput | $675,000 | – | 500,000 | +100.0% | 0.02% | – |
VRNA | New | VERONA PHARMA PLCcall | $675,000 | – | 500,000 | +100.0% | 0.02% | – |
MRTX | New | MIRATI THERAPEUTICS INCcall | $690,000 | – | 200,000 | +100.0% | 0.02% | – |
XBI | Buy | SPDR SER TRput | $137,500 | -98.2% | 150,000 | +50.0% | 0.00% | -98.2% |
VERU | Sell | VERU INC | $106,955 | -97.9% | 89,878 | -97.9% | 0.00% | -98.0% |
MOTUS GI HLDGS INC | $60,318 | -31.2% | 90,027 | 0.0% | 0.00% | -33.3% | ||
CMAXW | CAREMAX INC*w exp 06/08/202 | $23,400 | -19.1% | 60,000 | 0.0% | 0.00% | 0.0% | |
EQRX INC*w exp 12/17/202 | $42,500 | -1.4% | 250,000 | 0.0% | 0.00% | 0.0% | ||
BTAI | New | BIOXCEL THERAPEUTICS INCcall | $10,987 | – | 439,500 | +100.0% | 0.00% | – |
SURROZEN INC*w exp 08/01/203 | $10,000 | -40.0% | 166,666 | 0.0% | 0.00% | – | ||
Exit | PEAR THERAPEUTICS INC | $0 | – | -900,548 | -100.0% | -0.01% | – | |
TARA | Exit | PROTARA THERAPEUTICS INC | $0 | – | -290,051 | -100.0% | -0.03% | – |
Exit | ATHENEX INC | $0 | – | -776,623 | -100.0% | -0.03% | – | |
CLOV | Exit | CLOVER HEALTH INVESTMENTS CO | $0 | – | -1,500,000 | -100.0% | -0.04% | – |
Exit | DARIOHEALTH CORP | $0 | – | -313,869 | -100.0% | -0.04% | – | |
LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -6,726,496 | -100.0% | -0.07% | – |
ADCT | Exit | ADC THERAPEUTICS SA | $0 | – | -1,495,805 | -100.0% | -0.09% | – |
BLI | Exit | PHENOMEX INC | $0 | – | -2,506,442 | -100.0% | -0.09% | – |
LABP | Exit | LANDOS BIOPHARMA INC | $0 | – | -14,869,915 | -100.0% | -0.13% | – |
AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -590,000 | -100.0% | -0.16% | – |
Exit | HILLEVAX INC | $0 | – | -406,024 | -100.0% | -0.20% | – | |
BLPH | Exit | BELLEROPHON THERAPEUTICS INC | $0 | – | -930,000 | -100.0% | -0.22% | – |
MORF | Exit | MORPHIC HLDG INC | $0 | – | -256,737 | -100.0% | -0.28% | – |
LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -2,280,709 | -100.0% | -0.30% | – |
Exit | CYTEK BIOSCIENCES INC | $0 | – | -1,289,534 | -100.0% | -0.35% | – | |
ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -50,000 | -100.0% | -0.38% | – |
RAIN | Exit | RAIN ONCOLOGY INC | $0 | – | -1,648,215 | -100.0% | -0.42% | – |
VBIV | Exit | VBI VACCINES INC CDA | $0 | – | -52,335,002 | -100.0% | -0.47% | – |
TERN | Exit | TERNS PHARMACEUTICALS INC | $0 | – | -1,350,000 | -100.0% | -0.47% | – |
BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -4,952,538 | -100.0% | -1.05% | – |
SNY | Exit | SANOFIsponsored adr | $0 | – | -768,101 | -100.0% | -1.23% | – |
RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -1,272,694 | -100.0% | -4.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NEUROCRINE BIOSCIENCES SHARES | 41 | Q2 2023 | 15.7% |
AMICUS THERAPEUTICS SHARES | 38 | Q2 2023 | 14.0% |
QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
ALDEYRA THERAPEUTICS SHARES | 34 | Q2 2023 | 3.3% |
GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
ADMA BIOLOGICS SHARES | 28 | Q2 2023 | 1.4% |
VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
FERRARI SHARES | 26 | Q2 2022 | 0.0% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Lyra Therapeutics, Inc. | June 02, 2023 | 12,757,563 | 25.8% |
MeiraGTx Holdings plc | May 16, 2023 | 11,406,563 | 19.1% |
CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
Cerevel Therapeutics Holdings, Inc. | April 25, 2023 | 9,918,068 | 6.3% |
Verona Pharma plc | April 20, 2023 | 4,462,666 | 5.6% |
VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
Bellerophon Therapeutics, Inc. | March 14, 2023 | 930,000 | 8.9% |
CymaBay Therapeutics, Inc. | March 10, 2023 | 5,278,962 | 5.6% |
REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2023-09-13 |
SC 13G | 2023-09-08 |
13F-HR/A | 2023-08-24 |
SC 13D/A | 2023-08-15 |
13F-HR | 2023-08-14 |
4 | 2023-06-23 |
4 | 2023-06-20 |
4 | 2023-06-12 |
4 | 2023-06-08 |
4 | 2023-06-06 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.